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bjectives We sought to magnetically tag endothelial progenitor cells (EPCs) with a clinical agent
nd target them to a site of arterial injury using a magnetic device positioned outside the body.
ackground Circulating EPCs are involved in physiological processes such as vascular re-endotheli-
lization and post-ischemic neovascularization. However, the success of cell therapies depends on
he ability to deliver the cells to the site of injury.
ethods Human EPCs were labeled with iron oxide superparamagnetic nanoparticles. Cell viability
nd differentiation were tested using ﬂow cytometry. Following ﬁnite element modeling computer
imulations and ﬂow testing in vitro, angioplasty was performed on rat common carotid arteries to
enude the endothelium and EPCs were administered with and without the presence of an external
agnetic device for 12 min.
esults Computer simulations indicated successful external magnetic cell targeting from a vessel
ith ﬂow rate similar to a rat common carotid artery; correspondingly there was a 6-fold increase in
ell capture in an in vitro ﬂow system. Targeting enhanced cell retention at the site of injury by
-fold at 24 h after implantation in vivo.
onclusions Using an externally applied magnetic device, we have been able to enhance EPC local-
zation at a site of common carotid artery injury. This technology could be more widely adapted to
ocalize cells in other organs and may provide a useful tool for the systemic injection of cell
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795ne of the current challenges in the biomedical sciences is
he localization of stem cells to sites of interest for the repair
f tissue damage. Cellular therapies are increasingly applied
n clinical trials, and in recent years the use of hematopoietic
rogenitors as repairing modules in the compromised car-
iovascular system has been the focus of considerable
ttention (1–3). In the context of ischemic heart disease,
hese efforts have led to modest success (4,5). However,
elivery to specific targets within the body generally remains
difficult task, in part due to low uptake at the site of injury.
s such, cell therapies would greatly benefit from method-
logies aimed at targeting and monitoring cell trafficking.
See page 803
Superparamagnetic iron oxide nanoparticles (SPIO) offer
ttractive possibilities in biomedicine as they can be incorpo-
ated into cells affording a controllable means of “tagging” (6).
hese particles lead to a marked decrease in the magnetic
esonance imaging (MRI) parameter T2* and the possibility of
isualizing their localization noninvasively on T2*-weighted
RI (7–9). Furthermore, the magnetic properties of SPIOs
llow them to be manipulated mechanically by a magnetic field
radient. This “action at a distance,” combined with the
ntrinsic penetrability of magnetic fields into human tissue,
pens up potential applications involving the transport of
agnetically tagged biological entities. Such tagging has to
ate mainly been the focus of drug delivery systems (10–12),
ncluding drug targeting in humans (13). Recent efforts on
ell targeting in the arterial circulation have been limited to
nimal models; to achieve cell capture, these have necessi-
ated the use of large nonbiodegradable micron-sized beads
14–16) or nanoparticle composites fabricated in-house
17), and in most cases, the additional introduction of
ermanent intravascular metallic devices not currently ap-
roved for human use (15–17). It may also be possible to
ttract gene-carrying cells to post-capillary venules of tu-
ors (18). However, the targeted delivery of progenitor cells
sing external magnetic devices and clinically approved
ron-bearing agents has not yet been accomplished.
Early endothelial progenitor cells (EPCs) derived from
D34/CD133 cells (19,20) have been shown to be
nvolved in post-ischemic neovascularization (21) and re-
ndothelialization, reducing neointima formation following
rterial injury (22). We chose to target EPCs to a site of rat
ommon carotid artery (CCA) injury, as localization of such
rogenitors to sites of vascular catheterization may help
revent post-angioplasty restenosis (23,24). Although vari-
us SPIO formulations have been used in the past, their future
se as clinical agents is not straightforward due to safety issues
aised by cell labeling and the use of transfection agents. To
bviate these concerns, we have chosen to label human EPCs
ith the U.S. Food and Drug Administration (FDA)- spproved nano-sized SPIO compound Endorem (Guerbet,
aris, France), the only agent to date that has been used to
onitor cells in humans using MRI (8).
ethods
ells. Human mononuclear cells (MNCs) were collected by
eukapheresis from peripheral blood of donors stimulated
ith granulocyte colony-stimulating factor (25). We mag-
etically isolated the CD133 progenitor cells using anti-
uman CD133 (epitope 1) microbeads (Miltenyi Biotec,
ergisch Gladbach, Germany). These beads are biodegrad-
ble and typically disintegrate after a few days in culture.
hen, EPCs were derived by culturing CD133 cells for up
o 21 days on fibronectin-coated plates (BD, Franklin
akes, New Jersey) in growth medium consisting of 20%
etal bovine serum/endothelial basal medium 2 (Lonza,
asel, Switzerland) and supplemented with fibroblast, insulin-
ike, and endothelial growth factors; ascorbic acid; heparin; and
ecombinant human vascular endothelial growth factor 165 (25
g/ml) (R&D Systems, Minne-
polis, Minnesota) (26). Growth
edia were supplemented with
ecombinant human stem cell fac-
or (100 ng/ml), rhFlt-3/Flk-2 li-
and (50 ng/ml), and recombi-
ant human interleukin 3 (10 ng/
l) (R&D Systems) for the first
2 h. MNCs were grown for 2 h
n serum-free Dulbecco’s modi-
ed eagle medium (Gibco, In-
itrogen, Carlsbad, California)
ollowed by removal of nonadher-
nt cells and culture of the adher-
nt fraction in 10% fetal bovine
erum/Dulbecco’s modified eagle medium. All blood samples
ere obtained with written consent and were approved by local
thics committees.
abeling of cells with SPIO. At day 9 of culturing, the
D133 cells were labeled with the FDA-approved SPIO
ndorem (also known as Feridex in the U.S.) (Guerbet)
sing 0.5 mg/ml SPIO in growth medium. Suspension
D133 cells were labeled for 24 h and adherent cells for
h. Additionally, adherent cells were labeled for 2 or 24 h
o increase the amount of iron in the cells. Mononuclear
ells were labeled with SPIO by overnight incubation.
abeled cells were washed twice in 15 ml phosphate-
uffered saline.
uantiﬁcation of cellular SPIO uptake. We used a supercon-
ucting quantum interference device (27) to measure the
mount of Fe3O4 in the cells. To separate SPIO signal from
ackground signal coming from the cells and media, mea-
urements were performed at –263oC. The samples were
Abbreviations
and Acronyms
CCA  common carotid
artery
EPC  endothelial progenitor
cell
FDA  Food and Drug
Administration
MNC  mononuclear cell
MRI  magnetic resonance
imaging/images
SPIO  superparamagnetic
iron oxideaturated in an applied field of 2-T, which was subsequently
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796emoved to leave the SPIO particles in a magnetized state.
omparison of this remnant signal with that of an undiluted
PIO sample of known Fe3O4 concentration allowed quan-
ification of Fe3O4 per cell.
agnetic actuation. Neodymium iron boron permanent
isk magnets (1.195-T, grade N35SH, Magnet Applica-
ions Ltd., Hertfordshire, United Kingdom) 22 mm in
iameter and 16 mm in height were used to test cell viability
nd differentiation following magnetic attraction. The
PIO-labeled EPCs were placed 1 mm from the magnet
urface (maximum: 19.8 T2/m). For the flow system and in
ivo magnetic targeting, a magnetic actuator was con-
tructed using 5 10  10  25-mm3 NdFeB grade N35
locks, attached together inside a machined aluminum
asing in a configuration of rotating magnetization (Hal-
ach array), which concentrates the force on 1 side of the
ctuator (28).
iability assays. The CellTiter 96 AQueous One Solution
ssay (Promega, Madison, Wisconsin) was performed after
4 h of magnetic attraction of labeled CD133 cells. The
etrazolium compound in this assay undergoes reduction to
colored formazan product by viable cells, primarily medi-
ted by reduced nicotinamide adenine dinucleotide phos-
hate (29). Colorimetric quantification of viability of sam-
les of 3  104 CD133 cells was performed using a
pectrophotometric microplate reader (GENios, Tecan
roup Ltd., Männedorf, Switzerland) (490 nm, at 4 h).
ample activity was normalized to the mean absorbance of
ontrol (no magnet). Cell apoptosis was analyzed using an
nnexin-V-fluorescein isothiocyanate/propidium iodide
ow cytometric assay (ApoTarget, Invitrogen).
low cytometry. Immunophenotypic characteristics of
D133 cells labeled with SPIO at day 10 were analyzed
ith a fluorescence-activated cell sorter (FACSCalibur,
D) at day 21 of cultivation. Cells pre-treated with crystal-
izable fragment receptor blocking reagent (Miltenyi Biotec)
ere stained using the following antihuman antibodies:
hycoerythrin (PE)-CD304 BDCA-4/neuropilin-1 (30),
iotin-CD144/vascular endothelial cadherin (Bender Med-
ystems Inc., Burlingame, California) with streptavidin-
uorescein isothiocyanate for endothelial differentiation;
E-CD14 and CD11b (BD Biosciences, San Jose, Califor-
ia) for monocytic differentiation. Fluorochrome- and dose-
atched isotypes were used as controls. Cells were sus-
ended in 20 mmol/l N-2-hydroxyethylpiperazine-N-2-
thanesulfonic acid/0.5% bovine serum albumin/phosphate-
uffered saline containing 10 g/ml 7-aminoactinomycin D
Sigma Aldrich, St. Louis, Missouri). The 7-aminoactino-
ycin D–positive, nonviable cells were excluded and 1  104
iable cells were scored per analysis (CellQuestPro, BD).
RI. The SPIO-labeled CD133 cells were embedded in
ow melting point agarose (0.5%, 37°C) at concentrations of
45, 165, 49.5, 16.5, and 0  103 cells/ml in 250-l
ppendorf tubes (Eppendorf North America, Westbury, tew York) and were cooled to 4°C. Suspension in agarose
llowed for homogeneous distribution of the cells. The
ubes were imaged in a 9.4-T horizontal bore Varian MRI
ystem (VNMRS, Varian Inc., Palo Alto, California) using
39-mm radiofrequency coil (RAPID Biomedical GmbH,
impar, Germany). The T2*-weighted images were ac-
uired using a spoiled gradient echo sequence (echo time
TE]  25 ms, repetition time [TR]  200 ms, flip angle
FA]  30, 5122 matrix). The T2* maps were obtained
rom 20 echo times (TE  2.5 to 30 ms, TR  200 ms,
A 30, 2562 matrix) and produced using the ImageJ MRI
nalysis Calculator plug-in (K. Schmidt, ImageJ, U.S.
ational Institutes of Health, Bethesda, Maryland).
omputer simulations and in vitro ﬂow system. Magnet
esigns for acquiring optimal magnetic field strength to
apture intravascular SPIO-labeled cells were modeled us-
ng Opera-2d and -3d (Cobham Technical Services, Au-
ora, Illinois) and COMSOL Multiphysics 3.1 (COMSOL
nc., Burlington, Massachusetts) software. Fluid flow rate,
ell size and Fe3O4 content, and distance of magnet from
he vessel were considered by solving for the Khan and
ichardson hydrodynamic drag force and the attractive
orce from the magnet, in parabolic nonpulsatile laminar
ow. Simulated cells were 10 m in diameter, 3.9 pg
e3O4/cell, within a circulating blood volume of 20 ml. Cell
apture was defined as approximation and contact with the
essel wall within the 50-mm length of the array. The
albach magnet design described earlier was assessed in an
n vitro flow system by placing 1  106/ml SPIO-labeled
lood MNCs (3.5 pg Fe3O4/cell) in peristaltic pump-driven
ow (10 ml/min, mean velocity: 0.4 m/s) using biocompat-
ble (ISO 10993) Tygon S-54 elastic microtubing (Saint-
obain Performance Plastics, Courbevoie, France). The
agnet array was placed at distances of 1 and 5 mm from
he tubing. The mean of 5 hemocytometer cell counts was
alculated. Digital images were acquired using a standard
issection microscope and a digital camera.
ascular injury and in vivo magnetic targeting. Male
prague-Dawley rats (n  13, 380 to 420 g) (Charles River
aboratories International, Wilmington, Massachusetts)
ere anaesthetized using midazolam (625 g/100 g) and
entanyl (40 g/100 g) supported by halothane at 0.5% to
% at 2 l/min oxygen. The left CCA was exposed at the
ifurcation to the external and internal carotid artery and a
-F embolectomy catheter (Edwards Lifesciences Corp.,
rvine, California) was advanced proximally through an
rteriotomy into the CCA. The catheter was inflated with
00 l of air and rotated as it was being retracted (31). The
PIO-labeled CD133 cells were labeled with 5-mol/l
ellTracker Green 5-chloromethylfluorescein diacetate
Invitrogen-Molecular Probes). This dye is activated by
ntracellular esterases and only stains viable cells. We
dministered 5  105 cells in the CCA, which was
emporarily clamped for 10 min with the magnet array
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797laced at a 5-mm distance. The circulation was restored and
he magnet removed after a further 2 min of magnetic
ctuation (n 5). Two types of controls were used: 1) CCA
njury was performed and labeled cells were injected without
agnetic actuation (n  6); and 2) magnetic attraction of
abeled cells was performed on uninjured vessels (n  2).
issues were retrieved 24 h later and fixed with 1%
-fluoro-phenylalanine/phosphate-buffered saline. All ex-
erimental procedures complied with the institutional
uidelines for animal experiments.
onfocal microscopy and quantitation of cell engraftment.
rteries were opened longitudinally and counterstained
ith 4=,6-diamidino-2-phenylindole (Vector Labs, Burlin-
ame, California). Total arterial surface confocal micro-
cope images were acquired using a Leica TCS SP2 confocal
icroscope. Reflectance scanning (32) was used to detect
ntracellular SPIO. Image processing was performed using
he Volocity imaging software (Improvision, Waltham,
assachusetts). Background correction was performed us-
ng the “rolling ball” algorithm implemented in ImageJ
oftware. Signal outliers were removed by application of a
especkle median filter (W.S. Rasband, ImageJ, U.S. Na-
ional Institutes of Health). To analyze cell engraftment,
-y-z scans were rendered into a 3-dimensional vector
raphic format; this enabled quantification the total volume
f CellTracker-labeled cells per artery. Cell counts were
alculated from the total volume based on a 10-m cell
iameter and are presented per square millimeter of arterial
urface area.
tatistical analyses. We used SPSS version 11.5.1 (SPSS
nc., Chicago, Illinois) and Prism version 4.02 (Graphpad
oftware Inc., San Diego, California). Data were inspected
isually and with the Shapiro-Wilk test for small samples to
ssess normality. The homogeneity of variance assumption
as evaluated with the Levene test. Mean values are quoted
ith the standard error of the mean, medians are quoted
ith the interquartile range (IQR). The p values reported
re 2-tailed and were considered statistically significant at
he 5% level (p 0.05). In the apoptosis assays, equivalence
esting was considered appropriate because the null hypoth-
sis was nondifference; 2 1-sided t tests were used with a 3%
quivalence limit at the 0.05 level (Schuirmann test). A
aximum acceptable difference of 3% was set a priori based
n 24-h serum-deprived positive control cells (3% mean
ncrease in early apoptosis, 16% increase in late apoptosis).
ther statistical tests are specified in context.
esults
ell labeling and biological assays. To demonstrate that the
agnetic force following Endorem labeling was large
nough to attract cells to the vessel wall through a liquid, we
ecorded the motion of labeled MNCs in real time as a sagnetic force was applied (Fig. 1). Rapid movement
oward the magnet was observed as the cells responded to
he applied force.
The CD133-derived EPC viability was normal follow-
ng labeling and magnetic attraction (Fig. 2A) and no
ncrease in apoptosis was observed (Fig. 2B) when the
mount of SPIO in the cells was controlled. Increased
abeling resulted in a decrease in viability following mag-
etic attraction (Fig. 2A). This may be explained by
orce-induced mechanical damage of intracellular structures
ontaining the iron nanoparticles (33). As shown in Figure
C, there was normal expression of endothelial (vascular
ndothelial cadherin, CD304/NP-1) and monocytic
CD14, CD11b) markers of differentiation, 10 days after
abeling. Using in vitro MRI, cells were visible on T2*-
eighted images at dilutions as low as 25 cells/mm2 and
aused a marked reduction in T2* values from 8 cells/mm2
Fig. 2D). Using a superconducting quantum interference
evice, we calculated that labeled cells contained on average
.9 pg Fe3O4 per cell. Given the magnetic field applied in
hese experiments and the iron content of the cells, it is
ossible to estimate a “cell-safe” magnetic force for EPCs
bove which there is a risk of compromising viability; this
as 9.3 pN per cell.
xternal magnet design. An important consideration in our
xperimental model is that the rat CCA is a nonsuperficial
tructure approximately 5-mm from the skin in which there
re large hydrodynamic forces acting on the cells, with peak
Figure 1. Magnetic Attraction Causes Translocation of SPIO-Labeled MNC
The estimated force is 19 pN per cell. (A) Video frames for t  0 (applica-
tion of magnet), 5, 10, and 15 s after exposure to the magnet. Relative
position of the magnet is displayed. (B) Count of cells in ﬁeld of view (20
objective). The cells transiently acquire a magnetic dipole moment and
experience intercell attraction, entering the ﬁeld of view in aggregates
(increase in count rate between 5 and 10 s). The cell count rate subse-
quently decreases as the suspension volume closest to the magnet is
depleted of cells. MNC  mononuclear cell; SPIO  superparamagnetic
iron oxide.ystolic blood flow rate up to 10 ml/min (34,35). However,
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798here is a rapid decline of magnetic force at increased target
issue distances, which poses a challenge to magnetic tar-
eting using external devices in vivo (6,11). To overcome
his issue, we chose a permanent magnetic actuator design
hat increases the force magnitude at large distances (Hal-
ach array). With this actuator placed at a 5-mm vertical
istance from the target tissue, a computed maximum 8.7
N force was applied on each cell, which is below the 9.3
N limit.
omputer simulations. We proceeded by modeling the dis-
ribution of magnetic forces at distances of 1 and 5 mm
rom the magnetic actuator (Fig. 3A) and simulated the
ydrodynamic and magnetic forces on intraluminal
D133 cells using finite element modeling. With the
Figure 2. Labeling of CD133 Cells With SPIO
(A) Viability assay following 24 h of magnetic attraction (n  4 per group, ana
viability when the standard labeling method was used (adherent cells labeled
Increased adherent cell labeling for 2 and 24 h resulted in a 20% and 75% dec
apoptosis rates compared with apoptosis rates in the control group, at speciﬁe
ing with a 3% apoptosis limit. (C) Surface marker expression (percentage of liv
of differentiation markers (CS vs. LS and CA vs. LA) for vascular endothelial cad
In vitro MRI; T2*-weighted images (i) and T2* maps (ii) with equivalent averag
adherent fraction; CI  conﬁdence intervals; CS  control nonlabeled suspens
ent fraction (C); LS  SPIO-labeled suspension fraction; MRI  magnetic reson
eter, sensitive to SPIO presence; other abbreviations as in Figure 1.essel placed 1 mm away from the actuator, 11% of flowing cells made contact with the endothelial surface at each pass
hrough the vessel. With the actuator at 5 mm, 2.3% of cells
ade contact. If the cells adhered at the contact site,
pproximately 50% of cells would be extracted from the
irculation within 15 min at 1 mm, or 60 min at 5 mm.
n vitro ﬂow system. We investigated the targeting ability of
he actuator in vitro at the 2 distances using a 10-ml/min
ow system. At 1 mm, cells accumulated above the points of
redicted maximum force within 1 min after initiation of
ow (Fig. 3B). These cell aggregates dissociated a few
econds after removal of the actuator. Targeting for 15 min
t 1 mm resulted in 252-fold increase in capture (mean 41
103  6  103 cells) versus control (mean  163  41
ells) specimens. At 5 mm, there was a 6-fold increase in
f variance with Tamhane T2 post hoc test). There was no notable effect on
h) when compared with the viability of the nonmagnet control group.
in viability after magnetic attraction, respectively. (B) Mean difference in
es after labeling and magnetic attraction. All groups passed equivalence test-
) at 10 days after labeling. No differences were observed on the expression
(VE-Cad, n  6), CD304 (NP1, n  6), CD14 (n  6), or CD11b (n  3). (D)
values plotted against cell concentration (iii). CA  control nonlabeled
ction; EA  early apoptosis; LA  late apoptosis (B) or SPIO-labeled adher-
maging; N  necrosis; SEM  standard error of the mean; T2*  MRI param-lysis o
for 1
rease
d tim
e cells
herin
e T2*
ion fra
ance iapture (mean  1,630  276 cells) versus nontargeted
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799ontrol (mean 281 21 cells) specimens after 1 h of flow
Fig. 3C).
xternal targeting in a small animal model. To investigate
he in vivo feasibility of magnetic targeting using external
agnets, we attempted to increase SPIO-CD133 cell en-
raftment to a site of rat CCA injury by placing the actuator
djacent to the ventral aspect of the animal’s neck. Images in
igures 4A and 4B display representative (median) confocal
cans of the arterial surface 24 h after cell delivery; there is
notable increase in cell retention following magnetic
argeting. High power magnification (Fig. 4D) confirmed
he presence of nucleated cells (using 4=,6-diamidino-2-
henylindole) and the presence of intracellular clusters of
PIO nanoparticles in CD133 cells was confirmed using
eflectance confocal microscopy (Fig. 4E). Application of an
xternal magnetic force using the actuator during and after
ell delivery increased CD133 cell engraftment to the
njured vascular surface by a factor of 5.4 (median  134,
QR: 47 to 362 cells/mm2) compared with cell delivery
ithout the magnet (median  25, IQR: 17 to 42 cells/
m2). In the absence of vascular injury (control studies), no
ells engrafted to the endothelial surface when the magnetic
Figure 3. Computer Models and In Vitro Flow System
(A) Magnet array in aluminum casing; 5 bar magnets with rotating magnetizat
or-coding of magnetic force magnitude, magnetic ﬁeld lines displaying 1-sided
capture (top, digital images) at 1 min of 10 ml/min ﬂow and corresponding f
predicted peaks of force magnitude at magnet junctions and cell aggregates w
252-fold increase in cell capture after 15 min of magnetic targeting at 1 mm; n
orange plot) and in vitro magnetic cell capture at 5 mm after 1 h of 10 ml/morce was applied (cell count  0). iiscussion
he concept of magnetic tagging and targeting could play
n important role for future advances in delivery and
oninvasive monitoring of cell-based therapeutic interven-
ions. This is the first attempt to use a clinically approved
gent to externally target EPCs in a high-flow system such
s the arterial vasculature. We chose to use EPCs for this
tudy as these may hold high therapeutic value for the
uture. Endothelial damage is an initiating event in many
ardiovascular disorders. Transplantation of these early
rogenitor cells, which resemble hemangioblasts in their
roperties of marker expression, proliferation, migration,
nd differentiation, may expand the therapeutic arsenal to
epair vessels or endothelium and improve perfusion of
schemic tissues by providing new progenitor cells capable of
esponding to angiogenic stimuli, and have recently been
sed for cardiac neovascularization in clinical trials (36–40).
n the majority of these and other studies on cardiac
egeneration, cells were administered via intracoronary in-
ection with “flow-stop” periods of several minutes to
op, digital image) and corresponding computer model (bottom), with col-
and 1 or 5 mm distance used in experiments (dotted lines). (B) In vitro cell
istribution along horizontal line 1 mm away from array (red plot), showing
the vessel at these points (arrows and close up). Graph (right) displays
p  0.003 (2-sample t test). (C) Force along the 5 mm horizontal line (left,
(right); n  4, p  0.017 (2-sample t test with Welch correction).ion (t
ﬂux,
orce d
ithin
 3,ncrease engraftment; yet it has been shown that despite this
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800aneuver, only 1% to 3% of the cells remain on site (1,41),
nd there is a pressing need for targeting strategies (42).
We have based our cell targeting technique on a biode-
radable iron oxide nanoparticle preparation, which should
acilitate transition to human studies, in contrast to other
onbiodegradable agents used in cell tracking (43,44) and
argeting applications (14–16). Previous investigations have
ndicated that application of a magnetic force on labeled
ells can distort intracellular membranes (33). We noted
hat the application of a magnetic force for 24 h had the
otential to compromise cell viability, an effect that was
ependent on the extent of iron loading. Although we did
ot evaluate this in the current study, we anticipate that
igher magnetic forces will be tolerable if applied for shorter
engths of time. By controlling iron uptake and the specific
esign of magnetic devices, we have been able to safely
ttract cells without affecting cell viability, apoptosis, or
ifferentiation in culture.
Most importantly, our data suggest that by tagging
uman EPCs with an FDA-approved agent, it is possible to
afely target them in static and flowing conditions in vitro
Figure 4. Magnetic Targeting Following Balloon Angioplasty
(A) Sample 2-dimensional tile, total surface area scanning of the luminal side o
targeting; 18 cells/mm2. (B) Cell delivery with targeting; 142 cells/mm2. Square
tation. Objects meeting signal intensity and volume threshold criteria are show
cells (green) adhering to the injured vascular intima. Cell nuclei are labeled w
cell showing SPIO-nanoparticles (yellow). (F) Magnetic targeting increased adh
sus to the nontargeted control group (n  6); p  0.017 (Wilcoxon-Mann-Whi
whiskers extend to the last value within 1.5 interquartile range from the quartnd in vivo. We have assembled and tested a specialized sxternal magnetic actuator using an in vitro flow system.
sing this actuator, we have also been able to enhance cell
ocalization following common carotid artery injury in an
nimal model; the increase in engraftment was 5-fold higher
han in control (nontargeted) cells. In this study, a flow
nterruption period was implemented, which is similar to
hose employed in clinical trials and is a favorable condition
or cell enrichment. Our computer simulations and in vitro
ata suggest that in the presence of high flow rates at the
arget area, very few cells are captured under nontargeted
onditions, which allows up to 252-fold enhancement in
itro using magnetic attraction, depending on the distance
f the target tissue. This highlights the potential for
xtensive targeting in the cardiovascular system, even in
reas of high blood velocity. Nevertheless, further in vivo
tudies are warranted to assess EPC engraftment in a
ariety of flowing conditions following peripheral intra-
enous injection. Our results also emphasize a key issue
egarding external targeting in vivo; invariably, cells
owing in vessels closer to the magnetic source than the
arget tissue will also be targeted (6). However, such cells
t common carotid artery following injury and cell delivery without magnetic
included for orientation. (C) A 3-dimensional reconstruction used for quanti-
ink. (D) High power magniﬁcation of specimen showing CellTracker-labeled
-diamino-2-phenylindole (blue). (E) Reﬂectance confocal image of a CD133
of SPIO-labeled, CD133-derived to the injured vascular intima (n  5) ver-
xact test). Medians are highlighted in red. Boxes represent the quartiles and
ross () represents a value at 581 cells/mm2. Abbreviation as in Figure 1.f a ra
box
n in p
ith 4,6
esion
tney ehould be released following removal of the magnetic
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801ource in the absence of an underlying biological mech-
nism to keep them engrafted, as observed both in our in
itro flow experiments and our noninjured control sub-
ects in vivo.
In the injured arteries, we were not able to provide a
ircumferential external magnetic force; previously this
roblem has been partially circumvented by axial rotation of
he animal (14). Despite this fact, we did not observe any
onsistent preferential targeting of the cells in the arterial
pecimens. This may be due to a combination of factors.
he broad distribution of magnetic targeting forces due to
he large size of the magnetic actuator compared with the
ize of the artery (at least 100o arc) is likely to disperse the
argeted cells. Small within-vessel variations in the extent of
amage, unrelated of the direction of the magnetic force,
ould further facilitate nondirectional engraftment. In ad-
ition, the flow during the 24-h recirculation period may
nable cells to migrate away from the targeted regions to
reas of more pronounced damage. Indeed, in a recent
tudy, despite the presence of an intravascular permanently
agnetized device for 24 h, iron-labeled cells were present
n the damaged areas adjacent to the device, as well as on
t (15).
The magnetic control of cells inside the vasculature is a
ascinating and promising concept. In this preliminary
eport, we have outlined the feasibility of external targeting
n the arterial circulation using a clinical-grade agent,
ringing this technology a step closer to intervention in
umans. Long-term studies will be necessary to investigate
he retention of the cells at the site of engraftment,
onfirming a functionally beneficial increase in healing
ollowing magnetic targeting. Ultimately, we envisage con-
urrent MR imaging and MR-based magnetic guidance of
abeled cells in the body, possibly in a manner similar to
agnetic guidance of intravascular catheters (45) and mag-
etic beads (46). This approach could augment localization
nd simultaneous monitoring of cells in other organ systems
uch as the heart or the brain and may prove complementary
o the systemic injection of cell therapies, thus expanding
he horizon of cardiovascular interventions and the future of
tem cell therapeutic strategies.
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APPENDIX
or more details regarding the methods and calculations used in this study,
lease see the online version of this article.
